Longeveron reports Q1 net loss of $4.7M; cash $15.8M; HLHS trial data expected August 2026

Longeveron Inc.

2026-Q1 EPS reported -$0.19 revenue$398,000

Revenue $0.4M, net loss $4.7M vs $5.0M prior year; cash $15.8M at March 31, 2026.
Phase 2b ELPIS II trial in HLHS on track for top-line results in August 2026.
Closed initial $15M of a $30M private placement led by Coastlands Capital and Janus Henderson.
Appointed Stephen H. Willard as CEO in February 2026; cash runway extends into Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.